FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200331374> ?p ?o ?g. }

• W4200331374 abstract "Background: In a recent randomized, phase 3 trial (CheckMate 9ER), nivolumab combined with cabozantinib significantly improved patient outcomes compared with sunitinib. However, the cost-effectiveness of these novel agents for untreated advanced renal cell carcinoma (aRCC) remains unknown. Materials and Methods: We constructed a microsimulation decision-analytic model to measure the healthcare costs and outcomes of nivolumab plus cabozantinib compared with those of sunitinib for patients with aRCC. The transition probability of patients was calculated from CheckMate 9ER using parametric survival modeling. Lifetime direct medical costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were estimated for nivolumab-plus-cabozantinib treatment compared with sunitinib from a US payer perspective. We conducted one-way and probabilistic sensitivity analyses and a series of scenario analyses to evaluate model uncertainty. Results: Nivolumab plus cabozantinib was associated with an improvement of 0.59 LYs and 0.56 QALYs compared with sunitinib. However, incorporating nivolumab plus cabozantinib into first-line treatment was associated with significantly higher lifetime costs ($483,352.70 vs. $198,320.10), causing the incremental cost-effectiveness ratio for nivolumab plus cabozantinib to be $508,987/QALY. The patients' age of treatment, first-line utility, and cost of nivolumab had the greatest influence on the model. The outcomes were robust when tested in sensitivity and scenario analyses. Conclusion: For aRCC, substituting nivolumab plus cabozantinib in the first-line setting is unlikely to be cost-effective under the current willingness-to-pay threshold ($150,000/QALY). Significant price decreases for nivolumab used in first-line therapy would be needed to drop ICERs to a more diffusely acceptable value." @default.
• W4200331374 created "2021-12-31" @default.
• W4200331374 creator A5019010418 @default.
• W4200331374 creator A5025387435 @default.
• W4200331374 creator A5035411778 @default.
• W4200331374 creator A5057587462 @default.
• W4200331374 creator A5081185599 @default.
• W4200331374 date "2021-12-13" @default.
• W4200331374 modified "2023-10-18" @default.
• W4200331374 title "Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States" @default.
• W4200331374 cites W1982967337 @default.
• W4200331374 cites W1985943243 @default.
• W4200331374 cites W2011746683 @default.
• W4200331374 cites W2022007357 @default.
• W4200331374 cites W2023952988 @default.
• W4200331374 cites W2043951092 @default.
• W4200331374 cites W2058056848 @default.
• W4200331374 cites W2067763315 @default.
• W4200331374 cites W2070487839 @default.
• W4200331374 cites W2080477888 @default.
• W4200331374 cites W2118677643 @default.
• W4200331374 cites W2127385754 @default.
• W4200331374 cites W2155824113 @default.
• W4200331374 cites W2222086386 @default.
• W4200331374 cites W2237254160 @default.
• W4200331374 cites W2558408743 @default.
• W4200331374 cites W2589633700 @default.
• W4200331374 cites W2749428689 @default.
• W4200331374 cites W2752568644 @default.
• W4200331374 cites W2755525655 @default.
• W4200331374 cites W2785885859 @default.
• W4200331374 cites W2792937256 @default.
• W4200331374 cites W2900705321 @default.
• W4200331374 cites W2911812451 @default.
• W4200331374 cites W2915456024 @default.
• W4200331374 cites W2991986029 @default.
• W4200331374 cites W3023072291 @default.
• W4200331374 cites W3045020094 @default.
• W4200331374 cites W3092591340 @default.
• W4200331374 cites W3093923068 @default.
• W4200331374 cites W3119235789 @default.
• W4200331374 cites W3119254082 @default.
• W4200331374 cites W3132994416 @default.
• W4200331374 cites W3134949580 @default.
• W4200331374 cites W3171183108 @default.
• W4200331374 doi "https://doi.org/10.3389/fphar.2021.736860" @default.
• W4200331374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34966275" @default.
• W4200331374 hasPublicationYear "2021" @default.
• W4200331374 type Work @default.
• W4200331374 citedByCount "4" @default.
• W4200331374 countsByYear W42003313742022 @default.
• W4200331374 countsByYear W42003313742023 @default.
• W4200331374 crossrefType "journal-article" @default.
• W4200331374 hasAuthorship W4200331374A5019010418 @default.
• W4200331374 hasAuthorship W4200331374A5025387435 @default.
• W4200331374 hasAuthorship W4200331374A5035411778 @default.
• W4200331374 hasAuthorship W4200331374A5057587462 @default.
• W4200331374 hasAuthorship W4200331374A5081185599 @default.
• W4200331374 hasBestOaLocation W42003313741 @default.
• W4200331374 hasConcept C112930515 @default.
• W4200331374 hasConcept C121608353 @default.
• W4200331374 hasConcept C126322002 @default.
• W4200331374 hasConcept C143998085 @default.
• W4200331374 hasConcept C2777472916 @default.
• W4200331374 hasConcept C2777701055 @default.
• W4200331374 hasConcept C2779490328 @default.
• W4200331374 hasConcept C2780030458 @default.
• W4200331374 hasConcept C2781064419 @default.
• W4200331374 hasConcept C3019080777 @default.
• W4200331374 hasConcept C71924100 @default.
• W4200331374 hasConceptScore W4200331374C112930515 @default.
• W4200331374 hasConceptScore W4200331374C121608353 @default.
• W4200331374 hasConceptScore W4200331374C126322002 @default.
• W4200331374 hasConceptScore W4200331374C143998085 @default.
• W4200331374 hasConceptScore W4200331374C2777472916 @default.
• W4200331374 hasConceptScore W4200331374C2777701055 @default.
• W4200331374 hasConceptScore W4200331374C2779490328 @default.
• W4200331374 hasConceptScore W4200331374C2780030458 @default.
• W4200331374 hasConceptScore W4200331374C2781064419 @default.
• W4200331374 hasConceptScore W4200331374C3019080777 @default.
• W4200331374 hasConceptScore W4200331374C71924100 @default.
• W4200331374 hasFunder F4320335497 @default.
• W4200331374 hasFunder F4320335880 @default.
• W4200331374 hasLocation W42003313741 @default.
• W4200331374 hasLocation W42003313742 @default.
• W4200331374 hasLocation W42003313743 @default.
• W4200331374 hasLocation W42003313744 @default.
• W4200331374 hasOpenAccess W4200331374 @default.
• W4200331374 hasPrimaryLocation W42003313741 @default.
• W4200331374 hasRelatedWork W2800114398 @default.
• W4200331374 hasRelatedWork W3109577649 @default.
• W4200331374 hasRelatedWork W3152520552 @default.
• W4200331374 hasRelatedWork W3161601890 @default.
• W4200331374 hasRelatedWork W3210028029 @default.
• W4200331374 hasRelatedWork W4210780560 @default.
• W4200331374 hasRelatedWork W4282567532 @default.
• W4200331374 hasRelatedWork W4283579579 @default.
• W4200331374 hasRelatedWork W4285598862 @default.
• W4200331374 hasRelatedWork W4362587156 @default.
• W4200331374 hasVolume "12" @default.

• next